Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer’s disease: a qualitative interview study

Abstract Background Recruitment and retention remain persistent challenges in Alzheimer’s disease (AD) clinical trials, particularly as studies increasingly focus on earlier disease stages and require longer participation and more invasive procedures. Understanding how trial enrollment and participa...

Descripció completa

Dades bibliogràfiques

Autors principals:	Elizabeth Merikle, Carrie Presnall, Todd Feaster, Robyn Moxon, Eric Siemers, Diana Kerwin, Stephanie Cline
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-03-01
Col·lecció:	Trials
Matèries:	Qualitative interview Clinical trial participation Gender Alzheimer’s disease Patient perspective Phase 1 clinical trial
Accés en línia:	https://doi.org/10.1186/s13063-026-09656-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!